198 related articles for article (PubMed ID: 17961187)
21. Chronic lymphocytic leukemia: a review of some new aspects of the biology, factors influencing prognosis and therapeutic options.
Herishanu Y; Polliack A
Transfus Apher Sci; 2005 Feb; 32(1):85-97. PubMed ID: 15737877
[TBL] [Abstract][Full Text] [Related]
22. Risk stratification in chronic lymphocytic leukemia.
Seiler T; Döhner H; Stilgenbauer S
Semin Oncol; 2006 Apr; 33(2):186-94. PubMed ID: 16616065
[TBL] [Abstract][Full Text] [Related]
23. Use of prognostic factors in risk stratification at diagnosis and time of treatment of patients with chronic lymphocytic leukemia.
Gowda A; Byrd JC
Curr Opin Hematol; 2006 Jul; 13(4):266-72. PubMed ID: 16755224
[TBL] [Abstract][Full Text] [Related]
24. Allogeneic hematopoietic stem-cell transplantation for chronic lymphocytic leukemia with 17p deletion: a retrospective European Group for Blood and Marrow Transplantation analysis.
Schetelig J; van Biezen A; Brand R; Caballero D; Martino R; Itala M; García-Marco JA; Volin L; Schmitz N; Schwerdtfeger R; Ganser A; Onida F; Mohr B; Stilgenbauer S; Bornhäuser M; de Witte T; Dreger P
J Clin Oncol; 2008 Nov; 26(31):5094-100. PubMed ID: 18711173
[TBL] [Abstract][Full Text] [Related]
25. Treatment of B-cell chronic lymphocytic leukaemia: current status and future perspectives.
Montserrat E; Bosch F; Rozman C
J Intern Med Suppl; 1997; 740():63-7. PubMed ID: 9350185
[TBL] [Abstract][Full Text] [Related]
26. Minimal residual disease assessment in chronic lymphocytic leukaemia.
Sayala HA; Rawstron AC; Hillmen P
Best Pract Res Clin Haematol; 2007 Sep; 20(3):499-512. PubMed ID: 17707836
[TBL] [Abstract][Full Text] [Related]
27. Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia.
Maddocks-Christianson K; Slager SL; Zent CS; Reinalda M; Call TG; Habermann TM; Bowen DA; Hoyer JD; Schwager S; Jelinek DF; Kay NE; Shanafelt TD
Br J Haematol; 2007 Nov; 139(3):398-404. PubMed ID: 17910629
[TBL] [Abstract][Full Text] [Related]
28. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication.
Bosch F; Ferrer A; Villamor N; González M; Briones J; González-Barca E; Abella E; Gardella S; Escoda L; Pérez-Ceballos E; Asensi A; Sayas MJ; Font L; Altés A; Muntañola A; Bertazzoni P; Rozman M; Aymerich M; Giné E; Montserrat E
Clin Cancer Res; 2008 Jan; 14(1):155-61. PubMed ID: 18172266
[TBL] [Abstract][Full Text] [Related]
29. Recent progress in the management of chronic lymphocytic leukemia.
Robak T
Cancer Treat Rev; 2007 Dec; 33(8):710-28. PubMed ID: 17904294
[TBL] [Abstract][Full Text] [Related]
30. Purine analogue-based chemotherapy regimens for second-line therapy in patients with chronic lymphocytic leukemia.
Lamanna N; Weiss MA
Semin Hematol; 2006 Apr; 43(2 Suppl 2):S44-9. PubMed ID: 16549114
[TBL] [Abstract][Full Text] [Related]
31. The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL).
Giannopoulos K; Schmitt M; Kowal M; Własiuk P; Bojarska-Junak A; Roliński J; Dmoszyńska A
Leuk Res; 2008 Dec; 32(12):1815-9. PubMed ID: 18499249
[TBL] [Abstract][Full Text] [Related]
32. Bendamustine in the treatment of chronic lymphocytic leukemia.
Knauf W
Expert Rev Anticancer Ther; 2009 Feb; 9(2):165-74. PubMed ID: 19192955
[TBL] [Abstract][Full Text] [Related]
33. Oral fludarabine and cyclophosphamide as front-line chemotherapy in patients with chronic lymphocytic leukemia. The impact of biological parameters in the response duration.
Laurenti L; Tarnani M; De Padua L; Efremov DG; Zini G; Garzia M; Piccirillo N; Chiusolo P; Sorà F; Innocenti I; Sica S; Leone G
Ann Hematol; 2008 Nov; 87(11):891-8. PubMed ID: 18587576
[TBL] [Abstract][Full Text] [Related]
34. The role of stem-cell transplantation in chronic lymphocytic leukemia risk-adapted therapy.
Giné E; Moreno C; Esteve J; Montserrat E
Best Pract Res Clin Haematol; 2007 Sep; 20(3):529-43. PubMed ID: 17707838
[TBL] [Abstract][Full Text] [Related]
35. R-etodolac (SDX-101) and the related indole-pyran analogues SDX-308 and SDX-309 potentiate the antileukemic activity of standard cytotoxic agents in primary chronic lymphocytic leukaemia cells.
Lindhagen E; Nissle S; Leoni L; Elliott G; Chao Q; Larsson R; Aleskog A
Cancer Chemother Pharmacol; 2007 Sep; 60(4):545-53. PubMed ID: 17186240
[TBL] [Abstract][Full Text] [Related]
36. Autologous stem cell transplantation for chronic lymphocytic leukemia.
Dreger P; Brand R; Michallet M
Semin Hematol; 2007 Oct; 44(4):246-51. PubMed ID: 17961723
[TBL] [Abstract][Full Text] [Related]
37. Revisiting the role of hematopoietic stem cell transplantation in chronic lymphocytic leukemia.
Santos ES; Masri M; Safah H
Expert Rev Anticancer Ther; 2005 Oct; 5(5):875-91. PubMed ID: 16221057
[TBL] [Abstract][Full Text] [Related]
38. Chronic lymphocytic leukaemia--the haematologic basis for diagnosis and treatment.
Jacobs P; Wood L
Hematology; 2002 Feb; 7(1):33-41. PubMed ID: 12171775
[TBL] [Abstract][Full Text] [Related]
39. In vitro activity of 20 agents in different prognostic subgroups of chronic lymphocytic leukemia--rolipram and prednisolone active in cells from patients with poor prognosis.
Lindhagen E; Norberg M; Kanduri M; Tobin G; Säisänen L; Aberg M; Gustafsson MG; Sundström C; Rosenquist R; Aleskog A
Eur J Haematol; 2009 Jul; 83(1):22-34. PubMed ID: 19245531
[TBL] [Abstract][Full Text] [Related]
40. [Chronic lymphocytic leukemia].
Leporrier M
Rev Prat; 2008 Nov; 58(17):1861-7. PubMed ID: 19157199
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
